Floating Collagen Gel Contraction Assay for Quantifying TGF-beta1-Induced Myofibroblast Contractility in Primary Human Dermal Fibroblasts

Conditions: untreated, TGF-beta1 (5 ng/mL), TGF-beta1 + SB-431542 (10 µM), SB-431542 alone, and a cell-free collagen gel (matrix control). Each condition uses n = 4 gels per biological replicate, with N = 3 independent biological replicates using fibroblasts from 3 different donors (or 3 passages of one validated primary line). Gel area is measured at 0, 2, 6, 12, 24, and 48 h. Gels are randomized to plate positions, and scanned-image area measurements are performed blinded with coded filenames. A parallel set is reserved for alpha-SMA Western blot/immunofluorescence.

BSL-1/BSL-2 for primary human cells (handle as potentially infectious per donor screening; use a class II cabinet). Collagen acid stocks and 0.5 M NaOH are corrosive — gloves and goggles, neutralize on ice. TGF-beta1 carrier contains HCl; DMSO enhances skin penetration. Western/IF reagents (paraformaldehyde, methanol) are hazardous — use a fume hood. Standard PPE: lab coat, nitrile gloves, eye protection. Decontaminate media/surfaces with 10% bleach; segregate chemical waste.

Untreated cell-laden gels define basal contraction. Cell-free collagen gel controls for passive matrix shrinkage (should show negligible area change). Vehicle control: DMSO and the TGF-beta1 carrier (4 mM HCl/0.1% BSA) matched to treatment volumes. Inhibitor specificity: SB-431542 alone tests for baseline effect, and TGF-beta1+SB-431542 tests blockade of the induced response. A molecular correlate control (alpha-SMA IF/Western) confirms that contraction tracks myofibroblast differentiation.

Cell-free gels should contract <5%. Untreated cell gels typically contract ~30-50% by 48 h. TGF-beta1 should increase contraction (e.g., ~60-80% by 48 h) and accelerate the early phase, while SB-431542 co-treatment should suppress the TGF-beta1 enhancement back toward untreated levels. alpha-SMA should be markedly higher in TGF-beta1 gels and reduced by SB-431542, correlating with contraction. Gel-area CV within a condition should be <15%.

• Primary human dermal fibroblasts (e.g., HDFa, ATCC PCS-201-012), passage 3-8
• DMEM, high glucose, with 10% FBS, 1% pen-strep (growth); DMEM/0.5% FBS for assay
• Rat-tail collagen type I, 3-4 mg/mL, on ice; final lattice 1.5 mg/mL
• 10x DMEM or 10x PBS + 0.5 M NaOH for neutralization; sterile water
• Recombinant human TGF-beta1, 5 ng/mL working (carrier 4 mM HCl/0.1% BSA)
• SB-431542, 10 mM stock in DMSO; 10 µM working
• DMSO vehicle, matched (<0.1% final)
• BSA fraction V, sterile
• 24-well plates, sterile spatula/pipette tip to release gels
• alpha-SMA antibody (clone 1A4) for confirmatory IF/Western
• Dulbecco's PBS, Trypsin-EDTA

To embed primary human dermal fibroblasts in a type I collagen lattice, release the gels to float freely, and quantify the time-dependent reduction in gel area as a measure of cell-generated contractile force, testing how TGF-beta1 stimulation (a pro-fibrotic, alpha-SMA-inducing cue) and ALK5/TGF-beta receptor inhibition with SB-431542 modulate contraction over 48 h.

1. Harvest fibroblasts and resuspend at 1 x 10^6 cells/mL in DMEM/0.5% FBS; keep on ice.
2. On ice, prepare a 1.5 mg/mL collagen mix: combine neutralized collagen, 10x DMEM, and water; verify pH 7.2-7.4; then add cells to 2 x 10^5 cells/mL final.
3. Dispense 0.5 mL of the cell-collagen mix per well of a 24-well plate; gel 45-60 min at 37 C.
4. Overlay each gel with 1 mL DMEM/0.5% FBS containing the appropriate treatment (untreated, TGF-beta1, TGF-beta1+SB-431542, SB-431542, or cell-free).
5. After 1 h equilibration, gently detach each gel from the well wall and bottom with a sterile spatula/tip so it floats freely. Record t = 0.
6. Scan or photograph the plate on a flatbed scanner / gel-doc with a ruler in frame at 0, 2, 6, 12, 24, and 48 h, keeping illumination and distance fixed.
7. Refresh treatments at 24 h.
8. At 48 h, collect a parallel gel set for alpha-SMA immunofluorescence/Western to correlate contraction with myofibroblast marker expression.

Independent variables: TGF-beta1 (+/-) and SB-431542 (+/-). Dependent variable: percent gel contraction = (initial gel area - gel area at t) / initial gel area x 100, plus alpha-SMA level. Controlled variables: collagen concentration (1.5 mg/mL) and pH, cell density (2 x 10^5/mL), gel volume, release timing, serum (0.5% FBS), imaging geometry/illumination, donor/passage, time points.

If collagen gel contraction reflects actomyosin-based contractile force from myofibroblast-differentiated fibroblasts, then TGF-beta1 (5 ng/mL) will accelerate and increase gel-area reduction relative to untreated controls, and co-treatment with the ALK5 inhibitor SB-431542 (10 µM) will block this TGF-beta1-driven enhancement back toward baseline, paralleling alpha-SMA expression.

Scanned images are analyzed in Fiji: each gel outline is segmented (threshold or wand tool) and area measured in mm^2 against the in-frame ruler scale; percent contraction is normalized to each gel's t = 0 area. Contraction rate is the slope during the linear early phase. alpha-SMA is quantified by mean fluorescence intensity (IF) or band densitometry normalized to GAPDH (Western). Filenames are coded before measurement to blind analysis.

Gels don't contract at all: cell density too low, serum too high masking response, or gels not fully released — confirm release from all edges and use 0.5% FBS. Gels tear during release: gel under-polymerized or handled roughly — extend gelling to 60 min and release gently around the rim first. Passive (cell-free) shrinkage high: collagen pH off or concentration too low — verify pH 7.2-7.4 and 1.5 mg/mL. No TGF-beta1 effect: cytokine inactive or fibroblasts already maximally differentiated — use fresh aliquots and lower-passage cells. Inconsistent area measurement: fix scanner distance/illumination and include a ruler in every image.

Percent contraction at 48 h (per-biological-replicate means, N = 3 donors) is compared by one-way ANOVA with Tukey's HSD across conditions (alpha = 0.05); the planned contrast is TGF-beta1 vs TGF-beta1+SB-431542. Time courses are analyzed by two-way repeated-measures ANOVA (time x treatment) with Sidak correction. Correlation between contraction and alpha-SMA is assessed by Pearson's r. Power analysis (alpha 0.05, power 0.8) indicates N = 3 donors x 4 gels detects a 20% absolute contraction difference given SD ~6%.